Using advanced MRI to improve bladder cancer treatment decisions
Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making
This study is testing whether advanced MRI can help doctors make better treatment choices for people with bladder cancer by providing clearer pictures of their tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 182 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Zurich, ZH) |
| Trial ID | NCT04533672 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of multiparametric Magnetic Resonance Imaging (mpMRI) to enhance the staging and treatment decision-making for bladder cancer patients. By combining advanced imaging techniques with genetic analyses of tumors, the study aims to provide a more personalized approach to treatment based on the specific characteristics of the cancer. Patients with confirmed or suspected bladder cancer will undergo mpMRI to assess their tumors more accurately, which may lead to better treatment outcomes. The study seeks to establish the effectiveness of mpMRI in differentiating between non-muscle-invasive and muscle-invasive bladder cancers.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed or suspected primary bladder cancer and a tumor size of at least 1.5 cm.
Not a fit: Patients with prior bladder treatments or those with non-MRI compatible implants will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more tailored and effective treatment strategies for bladder cancer patients.
How similar studies have performed: While the use of MRI in cancer staging is established, the specific combination of mpMRI and genetic analysis in bladder cancer is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with confirmed or suspected primary bladder cancer and a circumscribed tumor/focal thickening of the bladder wall on initial imaging (ultrasound, CT) or cystoscopy with an approx. size of ≥ 1.5 cm/for which at least 2-3 TUR-B resection loops are necessary * Informed consent as documented by signature (Informed Consent Form) Exclusion Criteria: * Prior TUR-B or other bladder treatment, prior treated bladder cancers, prior pelvic irradiation * Women who are pregnant or breast-feeding. Female participants who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of childbearing potential. * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Previous enrolment into the current study * Patients with non-MRI compatible metallic or electronic implants, devices or metallic foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or other non-MRI compatible implants).
Where this trial is running
Zurich, ZH
- University Hospital Zurich — Zurich, Zh, Switzerland (Recruiting)
Study contacts
- Study coordinator: Andreas Hötker, MD
- Email: andreas.hoetker@usz.ch
- Phone: +41 44 255 29 20
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.